Golcadomide (GOLCA; CC-99282), a Novel CELMoD Agent, Plus R-CHOP in Patients (pts) with Previously Untreated Aggressive B-Cell Lymphoma (a-BCL): Safety and Efficacy Results from Phase 1b Dose Expansion
Author:
Marc S. Hoffmann,Javier L. Munoz,Jason Westin,Theodoros Vassilakopoulos,Alejandro Martin Garcia-Sancho,Antonio Rueda Dominguez,Wojciech Jurczak,Su-Peng Yeh,Maria Bouzani,Argyrios Gkasiamis,Mark Kaplan,Arpankumar Patel,Floriane Boucaud,Ju Li et al.
Copyright © 2023 The American Society of Hematology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.